JP7698318B2 - Ｖｉｐｒ２アンタゴニストペプチド - Google Patents

Ｖｉｐｒ２アンタゴニストペプチド Download PDF

Info

Publication number
JP7698318B2
JP7698318B2 JP2022511913A JP2022511913A JP7698318B2 JP 7698318 B2 JP7698318 B2 JP 7698318B2 JP 2022511913 A JP2022511913 A JP 2022511913A JP 2022511913 A JP2022511913 A JP 2022511913A JP 7698318 B2 JP7698318 B2 JP 7698318B2
Authority
JP
Japan
Prior art keywords
leu
group
peptide
pro
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022511913A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021200259A1 (https=
Inventor
孝太郎 坂元
由希夫 吾郷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichimaru Pharcos Co Ltd
Original Assignee
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichimaru Pharcos Co Ltd filed Critical Ichimaru Pharcos Co Ltd
Publication of JPWO2021200259A1 publication Critical patent/JPWO2021200259A1/ja
Priority to JP2025095125A priority Critical patent/JP2025120320A/ja
Application granted granted Critical
Publication of JP7698318B2 publication Critical patent/JP7698318B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022511913A 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド Active JP7698318B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025095125A JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020059721 2020-03-30
JP2020059721 2020-03-30
PCT/JP2021/011316 WO2021200259A1 (ja) 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025095125A Division JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Publications (2)

Publication Number Publication Date
JPWO2021200259A1 JPWO2021200259A1 (https=) 2021-10-07
JP7698318B2 true JP7698318B2 (ja) 2025-06-25

Family

ID=77928204

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022511913A Active JP7698318B2 (ja) 2020-03-30 2021-03-19 Ｖｉｐｒ２アンタゴニストペプチド
JP2025095125A Pending JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025095125A Pending JP2025120320A (ja) 2020-03-30 2025-06-06 Ｖｉｐｒ２アンタゴニストペプチド

Country Status (5)

Country Link
US (1) US20230174582A1 (https=)
EP (1) EP4137502A4 (https=)
JP (2) JP7698318B2 (https=)
CN (1) CN115298194A (https=)
WO (1) WO2021200259A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7339471B1 (ja) * 2022-02-25 2023-09-05 一丸ファルコス株式会社 癌転移抑制用のｖｉｐｒ２アンタゴニストペプチド
JP7417010B1 (ja) * 2022-03-31 2024-01-17 国立大学法人 香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512530A (ja) 2000-10-23 2004-04-22 ザ　プロクター　アンド　ギャンブル　カンパニー 血管活性腸管ペプチド受容体を用いて筋量または筋機能を調節する化合物を同定するための方法
JP2008510679A (ja) 2004-06-16 2008-04-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
JP2009519212A (ja) 2005-10-26 2009-05-14 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
RU2393167C2 (ru) * 2004-06-16 2010-06-27 Джи-И Хелткер АС Пептидные соединения
WO2018052002A1 (ja) * 2016-09-13 2018-03-22 第一三共株式会社 Ｔｈｒｏｍｂｏｓｐｏｎｄｉｎ １結合ペプチド
CN108218971B (zh) * 2016-12-21 2021-01-22 海南大学 α-芋螺毒素肽TxID新突变体、其药物组合物及用途
JP7417010B1 (ja) * 2022-03-31 2024-01-17 国立大学法人 香川大学 癌免疫増強用のｖｉｐｒ２アンタゴニストペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512530A (ja) 2000-10-23 2004-04-22 ザ　プロクター　アンド　ギャンブル　カンパニー 血管活性腸管ペプチド受容体を用いて筋量または筋機能を調節する化合物を同定するための方法
JP2008510679A (ja) 2004-06-16 2008-04-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
JP2009519212A (ja) 2005-10-26 2009-05-14 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS，2018年08月01日，Vol. 503，pp. 1973-1979
BIOPOLYMERS (PEPTIDE SCIENCE)，2016年05月14日，Vol. 106, No. 6，pp. 843-852
CHEM. SOC. REV.，2014年09月08日，Vol. 44，pp. 91-102
NATURE CHEMISTRY，2014年08月31日，Vol. 6，pp. 1009-1016

Also Published As

Publication number Publication date
JPWO2021200259A1 (https=) 2021-10-07
JP2025120320A (ja) 2025-08-15
US20230174582A1 (en) 2023-06-08
CN115298194A (zh) 2022-11-04
EP4137502A4 (en) 2024-02-28
EP4137502A1 (en) 2023-02-22
WO2021200259A1 (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
AU2010310665B2 (en) Peptidic GLP-2 agonists
TW202321275A (zh) 介白素—２３受體之雙環肽抑制劑
CN103533949B (zh) 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂
JP2025120320A (ja) Ｖｉｐｒ２アンタゴニストペプチド
TW201326200A (zh) 擬肽巨環化合物
CN114787183A (zh) 肠促胰岛素类似物及其用途
CN102573888A (zh) 长效y2 受体激动剂
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
WO2020230780A1 (ja) Ｒａｓ阻害ペプチド
US8592374B2 (en) Neurotrophic peptides
US20040122013A1 (en) Analogs of nocicettin
WO2022171098A1 (zh) 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
RU2540012C2 (ru) Мотилин-подобное пептидное соединение, обладающее приданной ему трансмукозальной абсорбционной способностью
JP2025102922A (ja) 新規ｌｒｐ１結合ペプチド
US10562935B2 (en) Stapled peptides and uses thereof
WO2024043249A1 (ja) 環状ペプチドまたはその塩、およびｍｄｍｘ阻害剤
US20130143809A1 (en) Neurotrophic peptides
WO2023022234A1 (ja) ヒトトランスフェリンレセプター結合ペプチド
KR20230031884A (ko) 형태적으로 제약된 α-RGIA 유사체
JP2024536413A (ja) 二環式ペプチドリガンド薬物コンジュゲート
WO2024043250A1 (ja) 環状ペプチドまたはその塩、およびｍｄｍｘ阻害剤
WO2024172166A1 (ja) ヒトトランスフェリンレセプター結合ペプチド
JPWO2015083816A1 (ja) 新規ｎｋ３受容体アゴニスト
HK40069562B (zh) 钙敏感受体激动剂化合物及其应用
Penke et al. Analogue and conformational studies on peptides, hormones and other biologically active peptides

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231120

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7698318

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150